BioPharma Clinical Trials
The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
Global pharmaceutical companies are racing to tap China’s new AI-powered biotech platforms to discover drugs faster and cheaper. In 2025, major Weste...
November 27, 2025 | Analysis
Mabwell Doses First Patient in Phase One Two Study of Novel CDH17 Targeting ADC 7MW4911 for Advanced Solid Tumours
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed...
November 26, 2025 | News
Otsuka Advances Centanafadine With FDA Filing To Bring a First in Class ADHD Therapy to Children, Adolescents, and Adults
Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents, and adults. It is a first-in-class norepinephrine, dop...
November 26, 2025 | News
Pin Therapeutics Begins First Human Study of CK1 Alpha Degrader PIN 5018 for Rare Cancer
Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced on November 20 that it has...
November 25, 2025 | News
Kelun Biotech Reports Strong Phase Three Success for Sac TMT and Keytruda in First Line Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that the Independent Data Monitoring Committee (IDMC) concluded t...
November 25, 2025 | News
AGC Biologics and AAVantgarde Forge New Partnership to Advance Dual AAV Gene Therapies for Inherited Blindness
Partnership accelerates AGC Biologics' leadership in the AAV market, applying its BravoAAV™ platform to complex gene therapies for inherited blindn...
November 24, 2025 | News
Pfizer and Astellas Gain Landmark FDA Approval for PADCEV and Keytruda in Cisplatin Ineligible Muscle Invasive Bladder Cancer
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of ca...
November 24, 2025 | News
Everest Medicines Begins Global Phase I Trial of EVM14 as First Patient Receives Dose in the United States
The first patient had received the first dose of EVM14 injection in a global, multi-center Phase I clinical trial of Everest Medicines' Tumor-Associated ...
November 24, 2025 | News
Henlius Therapy Wins Breakthrough Designation as First Immunotherapy Led Perioperative Regimen for Gastric Cancer
The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. The world's first gastric cancer p...
November 21, 2025 | News
ReviR Therapeutics Wins CIRM Grant to Advance First in Class Dual Target Therapy for Huntington’s Disease
ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced that it has been awarded a $4....
November 21, 2025 | News
CRScube Acquires Mednet to Build a Unified Global eClinical Platform Across Asia and North America
CRScube has announced the successful acquisition of Mednet, marking a key milestone in its global strategic growth and expansion into the North Ameri...
November 20, 2025 | News
Kazia Reports Initial Immune Complete Response in Stage IV Triple Negative Breast Cancer Under Expanded Access Combination Regimen
Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, announced that a patient with stage IV triple-negative breast canc...
November 20, 2025 | News
AGC Biologics and Repair Biotechnologies Partner to Advance a Novel mRNA Therapy for Atherosclerotic Disease
Partnership leverages AGC Biologics’ cost-effective and dependable cGMP mRNA and LNP capabilities AGC Biologics announced it is partnering w...
November 20, 2025 | News
AbbVie Secures Approval for EPKINLY in Combination With R2 as the First Bispecific Therapy for Relapsed or Refractory Follicular Lymphoma
EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available f...
November 19, 2025 | News
Most Read
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
